FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140012944> ?p ?o ?g. }

• W2140012944 endingPage "1099" @default.
• W2140012944 startingPage "1092" @default.
• W2140012944 abstract "<h3>Background</h3> Fatigue is a common and troubling symptom for people with multiple sclerosis (MS). <h3>Aim</h3> To evaluate the effectiveness and cost-effectiveness of a six-session group-based programme for managing MS-fatigue (Fatigue: Applying Cognitive behavioural and Energy effectiveness Techniques to lifeStyle (FACETS)). <h3>Methods</h3> Three-centre parallel arm randomised controlled trial with economic evaluation. Patients with MS and significant fatigue were randomised to FACETS plus current local practice (FACETS) or current local practice alone (CLP), using concealed computer-generated randomisation. Participant blinding was not possible. Primary outcomes were fatigue severity (Fatigue Assessment Instrument), self-efficacy (Multiple Sclerosis-Fatigue Self-Efficacy) and disease-specific quality of life (Multiple Sclerosis Impact Scale (MSIS-29)) at 1 and 4 months postintervention (follow-up 1 and 2). Quality adjusted life years (QALYs) were calculated (EuroQoL 5-Dimensions questionnaire and the Short-form 6-Dimensions questionnaire). <h3>Results</h3> Between May 2008 and November 2009, 164 patients were randomised; primary outcome data were available for 146 (89%). Statistically significant differences favour the intervention group on fatigue self-efficacy at follow-up 1 (mean difference (MD) 9, 95% CI (4 to 14), standardised effect size (SES) 0.54, p=0.001) and follow-up 2 (MD 6, 95% CI (0 to 12), SES 0.36, p=0.05) and fatigue severity at follow-up 2 (MD −0.36, 95% CI (−0.63 to −0.08), SES −0.35, p=0.01) but no differences for MSIS-29 or QALYs. No adverse events reported. Estimated cost per person for FACETS is £453; findings suggest an incremental cost-effectiveness ratio of £2157 per additional person with a clinically significant improvement in fatigue. <h3>Conclusions</h3> FACETS is effective in reducing fatigue severity and increasing fatigue self-efficacy. However, it is difficult to assess the additional cost in terms of cost-effectiveness (ie, cost per QALY) as improvements in fatigue are not reflected in the QALY outcomes, with no significant differences between FACETS and CLP. The strengths of this trial are its pragmatic nature and high external validity. <h3>Trial registration:</h3> Current Controlled Trials ISRCTN76517470." @default.
• W2140012944 created "2016-06-24" @default.
• W2140012944 creator A5000961276 @default.
• W2140012944 creator A5003874162 @default.
• W2140012944 creator A5046539019 @default.
• W2140012944 creator A5046804633 @default.
• W2140012944 creator A5058017052 @default.
• W2140012944 creator A5059276248 @default.
• W2140012944 creator A5066948116 @default.
• W2140012944 creator A5069600752 @default.
• W2140012944 creator A5070069898 @default.
• W2140012944 creator A5071000646 @default.
• W2140012944 creator A5071425254 @default.
• W2140012944 date "2013-05-21" @default.
• W2140012944 modified "2023-10-06" @default.
• W2140012944 title "A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis" @default.
• W2140012944 cites W1965789873 @default.
• W2140012944 cites W1970963099 @default.
• W2140012944 cites W1973185874 @default.
• W2140012944 cites W1977733462 @default.
• W2140012944 cites W1991209103 @default.
• W2140012944 cites W1994222210 @default.
• W2140012944 cites W2001049433 @default.
• W2140012944 cites W2003189347 @default.
• W2140012944 cites W2004816117 @default.
• W2140012944 cites W2007798912 @default.
• W2140012944 cites W2022388101 @default.
• W2140012944 cites W2036509055 @default.
• W2140012944 cites W2063797858 @default.
• W2140012944 cites W2083081439 @default.
• W2140012944 cites W2092052931 @default.
• W2140012944 cites W2092996951 @default.
• W2140012944 cites W2095809030 @default.
• W2140012944 cites W2108624530 @default.
• W2140012944 cites W2114242035 @default.
• W2140012944 cites W2128245375 @default.
• W2140012944 cites W2134120248 @default.
• W2140012944 cites W2134468324 @default.
• W2140012944 cites W2151630317 @default.
• W2140012944 cites W2161341360 @default.
• W2140012944 cites W2315429401 @default.
• W2140012944 cites W4250329983 @default.
• W2140012944 cites W4292806894 @default.
• W2140012944 doi "https://doi.org/10.1136/jnnp-2012-303816" @default.
• W2140012944 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3786656" @default.
• W2140012944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23695501" @default.
• W2140012944 hasPublicationYear "2013" @default.
• W2140012944 type Work @default.
• W2140012944 sameAs 2140012944 @default.
• W2140012944 citedByCount "102" @default.
• W2140012944 countsByYear W21400129442013 @default.
• W2140012944 countsByYear W21400129442014 @default.
• W2140012944 countsByYear W21400129442015 @default.
• W2140012944 countsByYear W21400129442016 @default.
• W2140012944 countsByYear W21400129442017 @default.
• W2140012944 countsByYear W21400129442018 @default.
• W2140012944 countsByYear W21400129442019 @default.
• W2140012944 countsByYear W21400129442020 @default.
• W2140012944 countsByYear W21400129442021 @default.
• W2140012944 countsByYear W21400129442022 @default.
• W2140012944 countsByYear W21400129442023 @default.
• W2140012944 crossrefType "journal-article" @default.
• W2140012944 hasAuthorship W2140012944A5000961276 @default.
• W2140012944 hasAuthorship W2140012944A5003874162 @default.
• W2140012944 hasAuthorship W2140012944A5046539019 @default.
• W2140012944 hasAuthorship W2140012944A5046804633 @default.
• W2140012944 hasAuthorship W2140012944A5058017052 @default.
• W2140012944 hasAuthorship W2140012944A5059276248 @default.
• W2140012944 hasAuthorship W2140012944A5066948116 @default.
• W2140012944 hasAuthorship W2140012944A5069600752 @default.
• W2140012944 hasAuthorship W2140012944A5070069898 @default.
• W2140012944 hasAuthorship W2140012944A5071000646 @default.
• W2140012944 hasAuthorship W2140012944A5071425254 @default.
• W2140012944 hasBestOaLocation W21400129441 @default.
• W2140012944 hasConcept C112930515 @default.
• W2140012944 hasConcept C118552586 @default.
• W2140012944 hasConcept C126322002 @default.
• W2140012944 hasConcept C159110408 @default.
• W2140012944 hasConcept C168563851 @default.
• W2140012944 hasConcept C1862650 @default.
• W2140012944 hasConcept C27415008 @default.
• W2140012944 hasConcept C2771230 @default.
• W2140012944 hasConcept C2779951463 @default.
• W2140012944 hasConcept C2780640218 @default.
• W2140012944 hasConcept C3019080777 @default.
• W2140012944 hasConcept C64332521 @default.
• W2140012944 hasConcept C71924100 @default.
• W2140012944 hasConcept C99508421 @default.
• W2140012944 hasConceptScore W2140012944C112930515 @default.
• W2140012944 hasConceptScore W2140012944C118552586 @default.
• W2140012944 hasConceptScore W2140012944C126322002 @default.
• W2140012944 hasConceptScore W2140012944C159110408 @default.
• W2140012944 hasConceptScore W2140012944C168563851 @default.
• W2140012944 hasConceptScore W2140012944C1862650 @default.
• W2140012944 hasConceptScore W2140012944C27415008 @default.
• W2140012944 hasConceptScore W2140012944C2771230 @default.
• W2140012944 hasConceptScore W2140012944C2779951463 @default.
• W2140012944 hasConceptScore W2140012944C2780640218 @default.

• next